Fast Melt Tablets Market Report 2026

The fast melt tablets market size has grown strongly in recent years. It will grow from $5.33 billion in 2025 to $5.74 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to difficulty swallowing conventional tablets, growth in pediatric and geriatric populations, early adoption in allergy and cns drugs, demand for rapid onset formulations, expansion of otc fast-dissolving medicines.

The fast melt tablets market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing focus on patient compliance, rising neurological and psychiatric disorders, demand for convenient drug delivery systems, expansion of homecare medication use, innovation in oral thin-film technologies. Major trends in the forecast period include rising demand for patient-friendly oral dosage forms, increasing use in pediatric and geriatric medications, expansion of cns and pain management applications, growing preference for water-free drug administration, wider adoption in travel-friendly and emergency use.

The increasing occurrence of heart attacks is expected to drive the growth of the fast melt tablets market in the coming years. A heart attack is a medical emergency that happens when blood flow to the heart muscle is obstructed, typically due to a blood clot or the accumulation of plaque in the coronary arteries. The frequency of heart attacks is rising because of higher consumption of processed foods, which contributes to elevated cholesterol levels and plaque buildup in the arteries. Fast melt tablets allow for rapid drug absorption, facilitating quicker delivery of essential medications such as aspirin or nitroglycerin to help prevent further damage during a heart attack, enhancing patient outcomes by restoring blood flow and reducing the risk of serious complications. For example, in September 2025, the British Heart Foundation, a UK-based cardiovascular research charity, reported that an additional one million people could be living with cardiovascular disease in the UK by 2030, increasing to two million more than today by 2040, representing the highest recorded figure. Consequently, the rising occurrence of heart attacks is fueling the growth of the fast melt tablets market.

Major companies operating in the fast melt tablets market are emphasizing formulation advancements, such as orally disintegrating tablet (ODT) technologies that allow rapid dissolution without water, to enhance medication adherence, convenience, and accessibility for patients with chronic neurological disorders. Orally Disintegrating Tablet (ODT) Technology enables active ingredients to be delivered in a fast-melt format that dissolves on the tongue within seconds, providing ease of administration for patients who have difficulty swallowing conventional tablets or require discreet, portable dosing options. For example, in February 2023, Cycle Pharmaceuticals Ltd., a U.K.-based rare disease and specialty pharmaceuticals company, introduced TASCENSO ODT (fingolimod), the first FDA-approved orally disintegrating tablet for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 years and older. Developed using Catalent’s ZYDIS fast-dissolve platform, the bioequivalent non-generic ODT ensures uninterrupted care for U.S. patients losing access to Gilenya support services and is supported by Cycle’s dedicated patient platform, Cycle Vita, which provides co-pay assistance, bridge programs, and in-home baseline assessments to maintain continuous fingolimod therapy.

In September 2023, Melt Pharmaceuticals, Inc., a US-based clinical-stage pharmaceutical company, signed a licensing agreement with Catalent Inc. Through this collaboration, Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet technology to create a sublingual, needle-free, and opioid-free formulation combining midazolam and ketamine. Catalent Inc. is a US-based provider of drug development and delivery solutions, specializing in biologics, gene therapies, and oral, inhalation, and injectable drug delivery technologies.

Major companies operating in the fast melt tablets market are Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Lannett Company Inc., Perrigo Company plc, Catalent Inc., SPI Pharma Inc., Fuji Chemical Industries Co. Ltd., Melt Pharmaceuticals Inc., Akina Inc., Church & Dwight Co. Inc., Windmill Health Products LLC, The Procter & Gamble Company, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd.

North America was the largest region in the fast melt tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fast melt tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fast melt tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the fast melt tablets market by increasing the cost of imported active pharmaceutical ingredients, flavoring agents, sweeteners, and specialized excipients used in rapid-dissolving formulations. These impacts have been most pronounced in branded cns and anti-allergy segments, particularly in north america and europe where excipient sourcing is globally diversified. Asia-pacific manufacturers have faced cost pressures due to dependency on imported formulation materials. However, tariffs have encouraged domestic excipient production and localized formulation manufacturing, improving supply stability.

The fast melt tablets market research report is one of a series of new reports that provides fast melt tablets market statistics, including fast melt tablets industry global market size, regional shares, competitors with a fast melt tablets market share, detailed fast melt tablets market segments, market trends and opportunities, and any further data you may need to thrive in the fast melt tablets industry. This fast melt tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fast melt tablets are oral dosage forms developed to dissolve rapidly in the mouth without requiring water. They provide a convenient alternative for patients who struggle to swallow conventional tablets. These tablets disintegrate swiftly, usually within seconds, when they come into contact with saliva. Fast melt technology is commonly applied in pediatric, geriatric, and travel-friendly medications.

The main categories of fast-melt tablets include antipsychotics, antiepileptics, central nervous system (CNS) stimulants, anxiolytics, anti-parkinsonian drugs, antihypertensives, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergy medications, proton pump inhibitors, and other types. Antipsychotics are drugs that regulate brain chemicals to manage schizophrenia, bipolar disorder, and related symptoms, and are often formulated as fast-melt tablets to enhance patient adherence. These tablets are used for a variety of indications, including pain relief, allergy and respiratory conditions, neurological disorders, gastrointestinal issues, cardiovascular diseases, and other medical conditions. They are available in multiple dosage forms, such as oral, sublingual, buccal, and chewable, and are utilized across different age groups, including adults, children, and the elderly. They are distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacy platforms.

The fast melt tablets market consists of sales of orally disintegrating tablets (ODTs), prescription medications, and over-the-counter (OTC) medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.